Cabaletta Bio
Cabaletta Bio
CABA
NASDAQ
5.63
USD
136.55%
About
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART).
CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial.
Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 985.1K |
| Three Month Average Volume | 27.4M |
| High Low | |
| Fifty-Two Week High | 26.35 USD |
| Fifty-Two Week Low | 3.4713 USD |
| Fifty-Two Week High Date | 08 Feb 2024 |
| Fifty-Two Week Low Date | 08 Aug 2024 |
| Price and Volume | |
| Current Price | 5.63 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | -20.58% |
| Thirteen Week Relative Price Change | -48.38% |
| Twenty-Six Week Relative Price Change | -78.64% |
| Fifty-Two Week Relative Price Change | -68.27% |
| Year-to-Date Relative Price Change | -79.06% |
| Price Change | |
| One Day Price Change | -2.76% |
| Thirteen Week Price Change | -44.75% |
| Twenty-Six Week Price Change | -76.51% |
| Five Day Price Change | -7.10% |
| Fifty-Two Week Price Change | -60.24% |
| Year-to-Date Price Change | -75.20% |
| Month-to-Date Price Change | -20.70% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 4.93898 USD |
| Book Value Per Share (Most Recent Quarter) | 4.13156 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 4.93898 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 4.13156 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -2.12227 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.65279 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.92455 USD |
| Normalized (Last Fiscal Year) | -1.65279 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.65279 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.92455 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.65279 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.92455 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 5.0446 USD |
| Cash Per Share (Most Recent Quarter) | 4.2083 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.61796 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.90403 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.6283 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 27.37% |
| Tangible Book Value (5 Year) | 48.03% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -52.51% |
| EPS Change (Trailing Twelve Months) | -11.45% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -203,225,000 |
| Net Debt (Last Fiscal Year) | -241,249,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 15 |
| Current Ratio (Most Recent Quarter) | 12 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -54,236,000 |
| Free Cash Flow (Trailing Twelve Months) | -75,661,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -36.52% |
| Return on Assets (Trailing Twelve Months) | -44.76% |
| Return on Assets (5 Year) | -33.76% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -39.72% |
| Return on Equity (Trailing Twelve Months) | -48.16% |
| Return on Equity (5 Year) | -38.17% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -39.22% |
| Return on Investment (Trailing Twelve Months) | -47.90% |
| Return on Investment (5 Year) | -35.68% |